Loading ....
Advancements in Nanoparticle and Liposome Applications for Cancer Immunotherapy
Published On 04/26/2024 4:10 PM
Overview of Nanoparticles and Liposomes
Nanoparticles, particularly those ranging from 1 to 100 nanometers, are ideal in optimizing drug delivery systems in oncology thanks to their ability to modify drug distribution and clearance. Liposomes, a subclass of nanoparticles, are biocompatible vesicles that encapsulate therapeutic agents, enhancing the delivery of both hydrophobic and hydrophilic drugs. Their design facilitates targeted delivery, reducing off-target effects and improving therapeutic outcomes, making them ideal for targeted drug delivery.Recent advancements in liposome technology include the development of ionizable lipids and high-throughput screening techniques that refine their pharmacokinetic properties. These enhancements improve liposome stability and targeting accuracy, crucial for their effectiveness in clinical applications.
Role of Nanoparticle in Cancer Immunotherapy
One of the most promising applications of nanoparticles is in cancer immunotherapy, where they help modulate the immune system to recognize and destroy cancer cells. Nanoparticles can deliver immunotherapeutic agents such as mRNA vaccines and checkpoint inhibitors precisely to immune cells or directly into tumors, thereby improving the immune system's ability to fight cancer. The development of lipid nanoparticles (LNPs) has played a key role in the delivery of mRNA vaccines, evidenced by the successful deployment of mRNA-based COVID-19 vaccines, setting a precedent for analogous approaches in cancer treatment.
Clinically Approved Liposomal Formulations
Several liposomal formulations have gained FDA approval for cancer treatment, demonstrating the clinical viability of this technology. For example, Doxil® (liposomal doxorubicin) is used in treating ovarian cancer, and Onivyde® (liposomal irinotecan) targets pancreatic cancer. These drugs illustrate how liposomes can improve therapeutic indices by enhancing drug delivery and minimizing toxicity.
Besides, Eganelisib (IPI-549) Liposomes represent a significant advancement in cancer immunotherapy by specifically targeting myeloid-derived suppressor cells (MDSCs) to modulate the tumor microenvironment. The dual encapsulation of IPI-549 with the photosensitizer chlorin e6 (Ce6) in liposomes has demonstrated efficacy in enhancing immunogenic photodynamic therapy and reducing the immunosuppressive activity of MDSCs, as detailed in the study "Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs-Targeting Immunotherapy of Colon Cancer." This approach not only inhibits tumor growth and increases cytotoxic T cell infiltration but also promotes dendritic cell maturation, offering a novel strategy that synergizes with immune checkpoint inhibitors to improve treatment outcomes in difficult-to-treat cancers.
Challenges and Future Perspectives
Despite these advancements, several challenges remain in the widespread adoption of nanoparticle-based therapies, such as difficulties with large-scale manufacturing, regulatory approvals, and the need for personalized therapy protocols. However, the future remains bright as ongoing research is dedicated to overcoming these obstacles and enhancing the precision of nanoparticle delivery systems. We stand with our customers as they explore advanced research, offering customized LNP synthesis services to support their projects and further facilitate the development and application of tailored therapeutic solutions.
The integration of nanoparticles and liposomes into cancer treatment regimens represents a significant advancement in medical science. Their capacity to deliver therapeutic agents holds substantial promise efficiently and safely for the evolution of cancer immunotherapy, with ongoing innovations expected to further enhance their clinical application.
Reference:
- 1. Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y. Liposomes: Advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020;154-155:102-122. doi: 10.1016/j.addr.2020.07.002. Epub 2020 Jul 8. PMID: 32650041.
- 2. Debele TA, Yeh CF, Su WP. Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators. Cancers (Basel). 2020 Dec 15;12(12):3773. doi: 10.3390/cancers12123773. PMID: 33333816; PMCID: PMC7765190.
- 3. Zong Y, Lin Y, Wei T, Cheng Q. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy. Adv Mater. 2023 Dec;35(51):e2303261. doi: 10.1002/adma.202303261. Epub 2023 Nov 1. PMID: 37196221.
- 4. Huang T, Peng L, Han Y, Wang D, He X, Wang J, Ou C. Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Front Immunol. 2022 Aug 26;13:922301. doi: 10.3389/fimmu.2022.922301. PMID: 36090974; PMCID: PMC9458914.
- 5. Wang C, Zhang Y, Dong Y. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications. Acc Chem Res. 2021 Dec 7;54(23):4283-4293. doi: 10.1021/acs.accounts.1c00550. Epub 2021 Nov 18. PMID: 34793124; PMCID: PMC10068911.
- 6. Ding D, Zhong H, Liang R, Lan T, Zhu X, Huang S, Wang Y, Shao J, Shuai X, Wei B. Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs-Targeting Immunotherapy of Colon Cancer. Adv Sci (Weinh). 2021 Jul;8(14):e2100712. doi: 10.1002/advs.202100712. Epub 2021 May 21. PMID: 34021727; PMCID: PMC8292876.
- 7. Liang J, Wang H, Ding W, Huang J, Zhou X, Wang H, Dong X, Li G, Chen E, Zhou F, Fan H, Xia J, Shen B, Cai D, Lan P, Jiang H, Ling J, Cheng Z, Liu X, Sun J. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Sci Adv. 2020 Aug 28;6(35):eabc3646. doi: 10.1126/sciadv.abc3646. PMID: 32923651; PMCID: PMC7455183.
This entry was posted in
Application and Technique Notes
